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Editorial on the Research Topic
Baclofen in the Treatment of Alcohol Use Disorder
Alcohol use disorder (AUD) is a severe illness for which available treatments are of limited efficacy. 
Over the last 20 years, baclofen has progressively emerged as a potentially useful treatment for AUD, 
but our knowledge on the best way to prescribe it, on potential influencing factors on its effects, 
and on its mechanism of action in AUD is still limited. Knowledge on its efficacy is also debated. 
As all three of us—RB, MH, and RA—have a long practice of baclofen use in the treatment of AUD, 
we thought of writing a special issue on this topic, and were delighted when Frontiers in Psychiatry 
accepted to give us this opportunity [two of us, RB and MH, have previously participated in the 
writing of a book on the same topic (1, 2)]. The realization of this new special issue has proved to be 
a kind of adventure we did not expect at the start.
We aimed at joining our competencies to provide a shared description of the methods to obtain 
an optimal therapeutic effect of baclofen in the treatment of AUD. We were aware that to obtain its 
therapeutic effect, the required dose of baclofen may largely vary among patients, certain patients 
requiring low doses and other high or very high doses. In other words, our experience showed that 
patients require “personalized doses” of baclofen that allow them to say “well, at this dose I have 
no more craving for alcohol, I do not experience craving when I see bottles or people who drink,” 
meaning that, following Olivier Ameisen’s words, the patient has reached a state of “indifference 
towards alcohol” (3).
Our special issue had three goals. The first was to give a general view of baclofen use for AUD 
treatment in different countries. The second was to provide joined information on the methods 
to prescribe baclofen in the treatment of AUD. The third was to obtain recent data from different 
research teams involved in various aspects of baclofen use in the treatment of AUD. To achieve these 
goals, we solicited the participation of a large number of baclofen prescribers worldwide.
For our first goal, Garbutt describes the use of baclofen in the US. According to this contribution, 
there is a limited use of baclofen to treat AUD in the US. However, Garbutt points out that there is, in 
general, a very low rate of medication use for the treatment of AUD in the US, largely due to a lack of 
knowledge of physicians and patients about the potential value of medications. Regarding baclofen, 
the results of meta-analyses showing that its efficacy is equivocal, the concerns of tolerability, and 
the fact that its prescription remains off label are all elements that may deter clinicians and patients. 
Garbutt nevertheless mentions that there are no accurate data on the use of baclofen in AUD in the 
US, making it difficult to know if clinicians prescribe it. These remarks probably apply to most other 
countries, except France, which is the only country where baclofen has an official approval from 
Health Authorities in the treatment of AUD, and where baclofen is more widely prescribed.
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For our second goal, we convened a large group of international 
experts, representative of researchers and physicians who 
contributed to the recent studies on baclofen and AUD. This 
group of experts achieved a consensus on the use of baclofen 
to treat AUD—“the Cagliari Statement”—published by Lancet 
Psychiatry in 2018 (4). After this concise and rigorous document, 
the group decided to provide a more detailed description of the 
different methods used to administer baclofen in the treatment of 
AUD (de Beaurepaire et al.). In detail, we describe how, especially 
in experimental studies, baclofen is usually administered in fixed 
doses to evaluate the efficacy and safety of each specific dose 
whereas, in clinical practice, baclofen is usually administered 
in flexible doses. In other words, the dose is gradually increased 
until the patient achieves the desired effects or side effects that 
prevent a further increase in dose. In this article, other than this 
description of the methods adopted for baclofen administration, 
there is also an unprecedented exhaustive review of published 
studies, approved by 26 authors coming from seven different 
countries (Australia, France, Germany, Great Britain, Italy, The 
Netherlands, and the US).
For our third goal, several innovative reports dealing with 
baclofen prescription and use, pharmacokinetics, preclinical 
research, and clinical investigations aiming to understand its 
potential mechanisms of action in AUD are published in the 
special issue. Reports on baclofen prescription and use include 
a long-term retrospective study (Pinot et al.); a research report 
on the response to baclofen in patients receiving antidepressants 
(Heng et al.); reviews on the effects of baclofen in alcohol 
withdrawal syndrome (AWS) (Cooney et al.), on the adverse 
effects of baclofen (Rolland et al.), and on the management of self-
poisoning with baclofen (Franchitto et al.); and reviews focused 
on comorbidities—with liver cirrhosis (Mosoni et al.) and other 
mental disorders (Agabio and Leggio). In a 3-year retrospective 
study, Pinot et al. have followed 144 patients with AUD receiving 
tailored doses of baclofen (50 to 520 mg/day; average dose, 
211 mg/day), and the treatment was successful in 63.3% of the 
patients (according to the WHO classification criteria) (Pinot et al.), 
a percentage of success grossly similar to that reported in other 
previously published observational studies. Depression and 
antidepressant treatment are common features in patients with 
AUD, and it was important to search for a potential interaction 
between baclofen and antidepressants. Heng et al. show that in 
patients on long-term treatment with antidepressants prior to 
starting baclofen, a beneficial effect on drinking outcomes can 
be shown like in patients who are not using antidepressants. 
However, there was a trend to an interaction between the two 
that needs further investigations (baseline tobacco use or alcohol 
liver disease may interfere with the interaction) (Heng et al.). The 
effectiveness of baclofen in the treatment of AWS is controversial, 
and Cooney et al., in their review, confirm that the evidence does 
not support the use of baclofen as a first-line treatment of AWS. 
Adverse effects too often limit or circumvent baclofen treatment, 
and this issue must be seriously considered. Rolland et al. propose 
a thoughtful review on baclofen adverse effects, separating the 
common and benign ones (sedation, insomnia, dizziness, and 
tinnitus) from the rare but potentially dangerous ones (seizures, 
mania, and sleep apnea), and point that concurrent consumption 
of alcohol, benzodiazepines, and other sedatives may worsen 
many adverse effects. These considerations have consequences 
on baclofen treatment management in terms of prevention of 
adverse effects and obtaining an optimal response (Rolland et al.). 
Cases of intentional or non-intentional baclofen self-poisoning 
have increased in parallel with the increasing use of baclofen in 
AUD. These cases present with particular clinical features that 
clinicians must be aware of. Franchitto et al. review the literature 
on that subject and address the management of this condition. 
AUD is often associated with liver cirrhosis and/or mental 
illnesses. AUD is difficult to treat in patients with liver cirrhosis 
because approved AUD medications may impair liver function. 
Baclofen is attractive because it has no liver toxicity, and Mosoni 
et al. review the clinical trials investigating the effect of baclofen 
in patients with AUD associated with liver disease. The results 
show a very favorable effect of baclofen in these patients, although 
the most appropriate dose of the drug remains to be determined 
(Mosoni et al.). Mental illness may alter the outcome in baclofen-
treated patients. Agabio and Leggio address this issue by using 
a narrative analysis of all clinical and human laboratory studies 
of baclofen treatment in patients with AUD with or without 
mental illness. The most frequent psychiatric comorbidities are 
anxiety and depression. Further work is needed to determine if 
these comorbidities interfere with baclofen treatment outcome 
(Agabio and Leggio).
Reports on baclofen pharmacokinetics include two studies 
by Simon et al. In their first article, Simon et al. investigate 
the pharmacokinetics of baclofen in 60 patients with AUD 
treated with various doses of baclofen (up to 300 mg/day). The 
results show that baclofen has a linear pharmacokinetic profile, 
corresponding to a one-compartment model, with no influencing 
clinical or biological factor (Simon et al.). In their second article, 
Simon et al. review the literature investigating the baclofen 
dose in relation to the pharmacokinetics of the drug. Indeed, 
the dose–response variability in baclofen-treated patients may 
be related to variability in pharmacokinetics. In particular, the 
effects of intestinal absorption, blood–brain barrier transport, 
and renal elimination are highlighted (Simon et al.).
Preclinical research is reviewed by Colombo and Gessa. 
Baclofen suppresses many alcohol-related behaviors in laboratory 
animals, including locomotor activity, alcohol drinking and 
self-administration, binge-like drinking, relapse drinking, 
alcohol seeking, and AWS symptoms. These effects of baclofen 
in animals provide interesting elements for the understanding 
of its mechanism of action in AUD (Colombo and Gessa). 
Two clinical studies also bring new data that could help the 
understanding of the mechanism of action of baclofen. Morley 
et al., using magnetic resonance spectroscopy, show that baclofen 
increases the concentrations of the antioxidants glutathione 
and N-acetyl aspartate in the brain of patients with AUD, and 
that higher glutathione levels predict favorable outcomes at 
follow-up. This supports the idea that the beneficial effects 
of baclofen in the treatment of AUD could be, at least in part, 
related to neuroprotective mechanisms (Morley et al.). Durant 
et al. show that the effects of an acute administration of baclofen 
are very different in patients with AUD compared with healthy 
controls. The measured effects were growth hormone release and 
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subjective experience (for instance, feeling “drunk”, “dizzy”, or 
“stimulated”). All these responses were blunted in patients with 
AUD while they were very marked in healthy controls. According 
to the authors, these results indicate a lower sensitivity to baclofen 
and, by extension, a general lower GABA-B receptor sensitivity 
in patients with AUD (Durant et al.). Finally, the potential 
mechanisms of baclofen in AUD are reviewed in an article that 
concludes that baclofen may produce an indifference to alcohol by 
suppressing the Pavlovian association between alcohol cues and 
rewards through an action in a critical part of the dopaminergic 
network (the amygdala). This action of baclofen is made possible 
by the fact that baclofen and alcohol act on similar brain systems 
(in particular GABA-B systems) (de Beaurepaire).
We really hope that this special issue will contribute to 
improve our knowledge and enhance debates and research on the 
use of baclofen in the treatment of AUD, a devastating illness that 
is dramatically undertreated.
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